Roidipedia.Compound reference & reporting
05 AUG 2026
CompoundsPharmaceutical Sibutramine
PharmaceuticalAnorecticWithdrawn drugSNRI

Sibutramine

Also known as Meridia · Reductil · Sibutrex

A serotonin-noradrenaline reuptake inhibitor marketed as Meridia/Reductil for weight loss from 1997. It produced modest, sustained weight loss but was withdrawn worldwide around 2010 after the SCOUT trial showed increased non-fatal heart attacks and strokes. It remains a common illegal adulterant in 'herbal' slimming products.

01 Overview

Sibutramine (and its active metabolites) inhibits reuptake of serotonin and noradrenaline, reducing appetite and modestly increasing energy expenditure. In trials it delivered roughly 3-5 kg more weight loss than placebo over a year, and it was widely prescribed for a decade.

The SCOUT (Sibutramine Cardiovascular Outcomes) trial in high-risk patients found a significant increase in non-fatal myocardial infarction and stroke, prompting EMA and FDA withdrawal in 2010. It is now banned as a medicine in most countries but is repeatedly detected illegally spiked into weight-loss supplements, causing avoidable cardiovascular harm.

02 Mechanism

Inhibits reuptake of serotonin and noradrenaline (and weakly dopamine) centrally, enhancing satiety and thermogenesis; raises heart rate and blood pressure as a class effect.

03 Dosing

TierDoseRouteNotes
Former therapeutic dose10–15 mg/dayOral10 mg once daily, titratable to 15 mg; withdrawn from market.

04 Effects

EffectMagnitudeEvidence
Sustained weight lossModest but durable weight loss with satiety enhancement and mild thermogenesis.~3-5 kg vs placebo/yearClinical
Improved glycaemic and lipid markersSecondary metabolic improvements accompanying weight loss.smallClinical

05 Side effects

EffectSeverityFrequencyEvidenceCountermeasures
Increased cardiovascular eventsSignificant excess of non-fatal myocardial infarction and stroke in high-risk patients, the reason for worldwide withdrawal.SevereIncreased vs placebo (SCOUT)Clinical
Hypertension and tachycardiaDose-related rise in blood pressure and pulse.ModerateCommonClinical

07 References

Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects (SCOUT)New England Journal of Medicine, 2010

08 Discussion0 comments

?
Sign in to add a comment…
Create account
Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.
This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.